BBIO Q3 2020 Earnings — BridgeBio Pharma, Inc. Revenue & Financial Results | Market Cap Arena

BBIOBridgeBio Pharma, Inc.

$14B

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$8M-69.6% YoY

Gross Profit

$8M100.0% margin

Operating Income

-$120M-1475.8% margin

Net Income

-$116M-1425.6% margin

EPS (Diluted)

$-0.98

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$132M

Free Cash Flow

-$132M

Stock-Based Comp.

$18M

Balance Sheet

Total Assets

$788M

Total Liabilities

$569M

Stockholders' Equity

$164M

Cash & Equivalents

$367M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$8M	$27M	-69.6%
Gross Profit	$8M	$24M	-66.5%
Operating Income	-$120M	-$55M	-119.9%
Net Income	-$116M	-$60M	-93.2%

Revenue Segments

License

$8M100%